Ascendis Pharma A/S Ordinary Share (ASND) Financials
Key financial figures for Ascendis Pharma A/S Ordinary Share (Q2 2026), as reported in EUR.
Ascendis Pharma A/S reported revenue of 344.9 million EUR for Q2 FY2026, up 118.2% from the same period a year earlier. Net income was 210.4 million EUR, or 3.08 EUR per share. Operating margin came to 18.39%, against -33.5% a year earlier. Free cash flow for the period was 283.1 million EUR. Across the last 5 reported quarters, quarterly revenue has risen from 158.0 million EUR in Q2 FY2025 to 344.9 million EUR in Q2 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Ascendis Pharma A/S are on the SentiSense financials page.
- Revenue
- EUR 345M
- Net Income
- EUR 210M
- EPS
- EUR 3.27
- Total Assets
- EUR 2.3B
- Operating Cash Flow
- EUR 286M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | EUR 345M | EUR 210M | EUR 3.08 | 18.39% | EUR 283M |
| Q1 FY2026 | EUR 251M | EUR 640M | EUR 9.91 | 10.06% | -EUR 16M |
| Q4 FY2025 | EUR 245M | -EUR 33M | -EUR 0.54 | 4% | EUR 67M |
| Q3 FY2025 | EUR 214M | -EUR 61M | -EUR 1.00 | 5.15% | EUR 2M |
| Q2 FY2025 | EUR 158M | -EUR 39M | -EUR 0.82 | -33.5% | -EUR 12M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | EUR 692M | -EUR 219M | -EUR 3.62 | -18.92% | EUR 44M |
| FY2024 | EUR 364M | -EUR 378M | -EUR 6.53 | -76.66% | -EUR 308M |
| FY2023 | EUR 267M | -EUR 481M | -EUR 8.55 | -170.79% | -EUR 470M |
Frequently asked questions
What was Ascendis Pharma A/S's revenue last quarter?
Ascendis Pharma A/S reported revenue of 344.9 million EUR for Q2 FY2026, up 118.2% from the same period a year earlier.
Is Ascendis Pharma A/S profitable?
Yes. Ascendis Pharma A/S reported net income of 210.4 million EUR for Q2 FY2026, a net margin of 61% on revenue.
How has Ascendis Pharma A/S's margin trended?
Operating margin was 18.39% in Q2 FY2026, compared with -33.5% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Ascendis Pharma A/S generate?
Ascendis Pharma A/S generated free cash flow of 283.1 million EUR in Q2 FY2026, after capital expenditure.
Figures are as reported by the filer in EUR and are not converted to US dollars. The share price is quoted in US dollars, so the two are not directly comparable.
Full income statement, balance sheet and cash flow for Ascendis Pharma A/S Ordinary Share on SentiSense, with up to forty quarters and twenty fiscal years of history.